Amicus Therapeutics (NASDAQ:FOLD) Insider Ellen Rosenberg Sells 23,621 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Ellen Rosenberg sold 23,621 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total transaction of $236,210.00. Following the sale, the insider directly owned 507,710 shares in the company, valued at approximately $5,077,100. The trade was a 4.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ellen Rosenberg also recently made the following trade(s):

• On Tuesday, November 25th, Ellen Rosenberg sold 36,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $360,000.00.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded up $0.15 during trading hours on Wednesday, reaching $10.02. The company’s stock had a trading volume of 3,136,374 shares, compared to its average volume of 4,236,660. The firm has a 50 day moving average price of $8.73 and a 200-day moving average price of $7.34. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The stock has a market cap of $3.09 billion, a P/E ratio of -83.49 and a beta of 0.66. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $10.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The company had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same quarter last year, the business posted $0.10 earnings per share. The firm’s revenue was up 19.5% on a year-over-year basis. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, analysts predict that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group boosted their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Thursday, September 18th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FOLD. Allianz Asset Management GmbH lifted its holdings in Amicus Therapeutics by 0.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after buying an additional 1,333 shares in the last quarter. Van ECK Associates Corp grew its stake in Amicus Therapeutics by 35.1% in the 3rd quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,466 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Amicus Therapeutics by 40.2% during the third quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 1,649 shares during the period. Gotham Asset Management LLC raised its stake in shares of Amicus Therapeutics by 1.5% during the third quarter. Gotham Asset Management LLC now owns 138,523 shares of the biopharmaceutical company’s stock valued at $1,092,000 after acquiring an additional 1,987 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Amicus Therapeutics by 2.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 2,263 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.